Michael Barbella, Managing Editor09.15.23
Fortis Life Sciences LLC has purchased Toronto-based International Point of Care Inc. (IPOC). Neither company disclosed the deal's financial terms.
IPOC develops and manufactures key components used in diagnostics, including lyophilized reagents, membranes, recombinant proteins, and controls. With this acquisition, Fortis can provide its customers with a customizable, end-to-end solution to advance their immunodiagnostic and molecular diagnostic products. IPOC’s recently expanded 36,000-square-foot facility is Fortis’ third GMP and ISO 13485 compliant manufacturing site in North America.
“Diagnostics and life sciences companies want a partner that can custom-design and validate reagents for their applications; control quality and cost with vertically integrated in-house manufacturing; and help them get their products to market faster,” Fortis Chief Business Officer Fred Pettijohn said. “IPOC perfectly complements our existing capabilities, and we are pleased to introduce our expanded solution to the market.”
“We are excited to join Fortis and offer our customers a complete suite of materials and services,” IPOC CEO David Ray added. “Our combined expertise fully supports the diagnostic industry’s advances in ultra-high-sensitivity, point-of-care, and multiplexing applications as well as in novel technologies such as quantitative lateral flow, isothermal amplification, and CRISPR-based diagnostics.”
IPOC specializes in developing and manufacturing diagnostic components. IPOC serves many of the leading global diagnostic companies enabling the commercialization of new immunodiagnostic and molecular diagnostic technologies.
Fortis partners with diagnostics and life sciences companies to custom design, validate, and manufacture proprietary solutions to solve their most difficult development problems. Fortis’ tailored approach and end-to-end capabilities accelerate the work of its customers as they bring the next generation of medicines and diagnostics to market. Fortis serves a global customer base and has offices across the world including four R&D sites and three GMP and ISO 13485 compliant manufacturing facilities in North America.
IPOC develops and manufactures key components used in diagnostics, including lyophilized reagents, membranes, recombinant proteins, and controls. With this acquisition, Fortis can provide its customers with a customizable, end-to-end solution to advance their immunodiagnostic and molecular diagnostic products. IPOC’s recently expanded 36,000-square-foot facility is Fortis’ third GMP and ISO 13485 compliant manufacturing site in North America.
“Diagnostics and life sciences companies want a partner that can custom-design and validate reagents for their applications; control quality and cost with vertically integrated in-house manufacturing; and help them get their products to market faster,” Fortis Chief Business Officer Fred Pettijohn said. “IPOC perfectly complements our existing capabilities, and we are pleased to introduce our expanded solution to the market.”
“We are excited to join Fortis and offer our customers a complete suite of materials and services,” IPOC CEO David Ray added. “Our combined expertise fully supports the diagnostic industry’s advances in ultra-high-sensitivity, point-of-care, and multiplexing applications as well as in novel technologies such as quantitative lateral flow, isothermal amplification, and CRISPR-based diagnostics.”
IPOC specializes in developing and manufacturing diagnostic components. IPOC serves many of the leading global diagnostic companies enabling the commercialization of new immunodiagnostic and molecular diagnostic technologies.
Fortis partners with diagnostics and life sciences companies to custom design, validate, and manufacture proprietary solutions to solve their most difficult development problems. Fortis’ tailored approach and end-to-end capabilities accelerate the work of its customers as they bring the next generation of medicines and diagnostics to market. Fortis serves a global customer base and has offices across the world including four R&D sites and three GMP and ISO 13485 compliant manufacturing facilities in North America.